NCT05016934View on ClinicalTrials.gov

Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

April 20, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

A vaccine composed of a recombinant S1 antigen

Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein

Sponsors
All Listed Sponsors
collaborator

Farmacore Biotecnologia Ltda

UNKNOWN

lead

Hospital do Coracao

OTHER